|
||
“GSK to stop paying doctors in major marketing overhaul.”By Ben Hirschler, Reuters. (Reuters) – GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff – a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit. Britain’s biggest drugmaker . . . → Read More: GSK to stop paying doctors in major marketing overhaul
“Annual Report to the Nation on the status of cancer.” Press Release, National Cancer Institute. The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate annually to provide updates on cancer incidence and death rates and trends in these outcomes . . . → Read More: Annual Report to the Nation on the status of cancer
“San Antonio Breast Cancer Symposium Highlights.” by Dr. Julie Gralow, #BCSM. The San Antonio Breast Cancer Symposium is the largest scientific meeting devoted to breast cancer, attracting national and international attention. It is attended by clinicians, researchers and advocates. “The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum . . . → Read More: San Antonio Breast Cancer Symposium Highlights by Dr. Julie Gralow
“Reflections on FDA Warning to 23andMe.” by Jim Evans, The Cancer letter. There’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic . . . → Read More: Reflections on FDA Warning to 23andMe
“Regulation Expert Weighs In on FDA Letter to 23andMe.” Mendelspod.com. On Monday, November 25th, the FDA sent a letter to the direct-to-consumer genetic testing company, 23andMe. The letter has received a bit more attention than the average FDA correspondence. The letter was addressed to 23andMe CEO, Anne Wojcicki, and told her that the company’s Personal . . . → Read More: Regulation Expert Weighs In on FDA Letter to 23andMe
“”Is it time to wash our hands of cause washing? Thoughts on Movember, Pinktober, Greenwashing, Catwashing?” By Nikki Reimer, Reimer Writes. There is a narrow line that all organizations must attend to when they enter the cause marketing realm. The Canadian Breast Cancer Foundation thinks that “the more public discussion about the issue, the greater . . . → Read More: “Is it time to wash our hands of cause washing? Thoughts on Movember, Pinktober, Greenwashing, Catwashing?
“In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted” By Roni Caryn Rabin, The New York Times. KFAR SABA, Israel — Ever since she tested positive for a defective gene that causes breast cancer, Tamar Modiano has harbored a mother’s fear: that she had passed it on to her two daughters. . . . → Read More: In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted
“Mammograms can help–and harm.” By H. Gilbert Welch, CNN. As part of breast cancer awareness month, a 40-year-old anchor had her first mammogram on morning television. And last week the anchor, Amy Robach, underwent a double mastectomy after announcing she had cancer, and saying — in front of 5 million viewers — that “having a . . . → Read More: Mammograms can help–and harm
“The Emperor of All Maladies”: Why Our Society Overfunds Internet Companies and Underfunds Cancer Research.” By Glen Kelman, LinkedIn.com. This post is part of a series in which Influencers describe the books that changed them. Follow the channel to see the full list. A few years ago, I was on a train to the airport . . . → Read More: “The Emperor of All Maladies”: Why Our Society Overfunds Internet Companies and Underfunds Cancer Research
“Will Extending the Women’s Health Initiative Lead to Better Research and Policy?” by Chloe Bird, Women’s Health Issues. In a time of scarce research dollars, securing support to sustain even highly successful research studies on women’s health is difficult, if not impossible. Yet, improving women’s health and health care requires data and answers to inform . . . → Read More: Will Extending the Women’s Health Initiative Lead to Better Research and Policy? |
||
| Copyright © 2026 Breast Cancer Consortium – Archives - All Rights Reserved. Privacy Policy | ||